© Globe Newswire
27.01.2026
QNRX
LISTED
XANS
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
News Preview
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
BAYN
LISTED
XETR
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
News Preview
Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two late-breaking sessions at the upcoming American Stroke Association’s International Stroke Conference (ISC) 2026. The conference will be held February 4-6 in New Orleans, Lou...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA i...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
27.01.2026
ICLR
LISTED
NASDAQ
ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership
News Preview
ICON plc (NASDAQ: ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois.
The new institute strengthens Accellacare’s ability to support oncology clinical trials and broaden access to innovative...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
27.01.2026
NEO
LISTED
NASDAQ
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
VEEV
LISTED
NYSE
Industry Research Finds Establishing a Foundation for AI is Top Priority for CPG Enterprises
News Preview
82% of organizations moving to unified platforms for standardized data and processes, AI readinessBARCELONA, Spain, Jan. 27, 2026 /PRNewswire/ -- A new industry report shows that building an AI-ready infrastructure is a top priority for consumer product goods (CPG) companies. The State of AI in Consumer Goods Report found most (82%) respondents ar...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
VEEV
LISTED
NYSE
Industry Research Finds Establishing a Foundation for AI is Top Priority for CPG Enterprises
News Preview
82% of organizations moving to unified platforms for standardized data and processes, AI readinessPLEASANTON, Calif., Jan. 27, 2026 /PRNewswire/ -- A new industry report shows that building an AI-ready infrastructure is a top priority for consumer product goods (CPG) companies. The State of AI in Consumer Goods Report found most (82%) respondents...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
AMRX
LISTED
NASDAQ
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
News Preview
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
LSTA
LISTED
NASDAQ
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
News Preview
Lisata regains full development rights to certepetide in the Greater China Region Lisata regains full development rights to certepetide in the Greater China Region...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
TEVA
LISTED
TLV
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
News Preview
PARSIPPANY, N.J., and TEL AVIV, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a partnership with actor, comedian and advocate, Will Forte, to increase awareness of Huntington’s disease (HD). HD, a rare, progressive neurological disorde...
Themefolio
Profiler
Peergroup
© Newsfile
27.01.2026
KPRX
LISTED
NASDAQ
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
News Preview
Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to its Scientific Advisory Board. As an advisor, Dr. Sakamoto, currently the Chair of Ophthalmology at Kagoshima University, will contribute cli...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
HCA
LISTED
NYSE
HCA Healthcare Reports Fourth Quarter 2025 Results and Provides 2026 Guidance
News Preview
HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the fourth quarter ended December 31, 2025.
Key fourth quarter metrics (all percentage changes compare 4Q 2025 to 4Q 2024 unless otherwise noted):
Revenues increased 6.7 percent to $19.513 billion
Net income attributable to HCA Healthcare, Inc. increased 3...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
27.01.2026
BCT
LISTED
TSX
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
News Preview
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new positive Phase 2 survival data highlighting multip...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
CYTK
LISTED
NASDAQ
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
News Preview
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
TGTX
LISTED
NASDAQ
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
News Preview
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 5 – 7, 2026 in San Diego, Californ...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
LXEO
LISTED
NASDAQ
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
News Preview
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Partnership for Cardiac RNA Therapies...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
CGTX
LISTED
NASDAQ
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
News Preview
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) on January 21, 2026. The objective of this meeting was to review pl...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
CRDF
LISTED
NASDAQ
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
News Preview
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC –...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
AXSM
LISTED
NASDAQ
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
News Preview
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S....
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
UNH
LISTED
NYSE
UnitedHealth Group Reports 2025 Results and Issues 2026 Outlook
News Preview
UnitedHealth Group (NYSE: UNH) today reported full year and fourth quarter 2025 results and issued its 2026 outlook.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126830491/en/
“We confronted challenges directly and finished 2025 as a much stronger company, giving us the momentum t...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
2096
LISTED
XETRA
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
News Preview
Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.Boehringer receives global rights to the asset, excluding great...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
2096
LISTED
XETRA
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
News Preview
Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.Boehringer receives global rights to the asset, excluding great...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
GLSI
LISTED
NASDAQ
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
News Preview
STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional update...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
JUNS
LISTED
NASDAQ
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
News Preview
JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
PSYG
LISTED
XCQ
Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf
News Preview
TORONTO, ON / ACCESS Newswire / January 27, 2026 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") announces that its proposed reverse takeover target, GoldCoast Resource Corp. ("GoldCoast"), has been granted a series of ten contiguous offshore reconnaissance licenses by the Minerals Commission of Ghana (the...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
POROF
LISTED
OTC
Cellev8 Receives Official Name Change by FINRA
News Preview
Preferred Commerce takes next steps with FINRA for Corporate Name Change to Cellev8 Nutrition Inc. (CELV) WELLINGTON, FL / ACCESS Newswire / January 27, 2026 / Preferred Commerce announced today that it has received final approval from the Financial Industry Regulatory Authority (FINRA) to change its corporate name to Cellev8 Nutrition Inc. (CELV),...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
CNSP
LISTED
NASDAQ
CNS Pharmaceuticals Issues Letter to Shareholders
News Preview
Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS PharmaceuticalsStrategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term Value Creation HOUSTON, TX / ACCESS Newswire / January 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
OSRH
LISTED
NASDAQ
OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries
News Preview
BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment by Woori IO's historical shareholders, and the initiation of a strategic review regarding a potential combination of its medical device subsidiaries...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.01.2026
ASBP
LISTED
NASDAQ
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks
News Preview
New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.Clopidogrel, currently sold under the brand name Plavix®, was the 41st most commonly prescribed medication in the United States, with more than 15.2 million combined branded and generic prescriptions in 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
ROG
LISTED
SIX
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
News Preview
Basel, 27 January 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
IBAB
LISTED
EURONEXT
IBA signs contract for a Proteus®ONE proton therapy system to be located at the MacKay Memorial Hospital in New Taipei City, Taiwan
News Preview
Louvain-La-Neuve, Belgium, January 27, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract for the supply of a Proteus®ONE1 compact proton therapy solution to be instal...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
IPN
LISTED
EURONEXT
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
News Preview
PARIS, FRANCE, 27 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Pierrick Lefranc will be appointed as Executive Vice President (EVP) and member of the Executive Leadership Team (ELT), as of 1 April 2026. Pierrick will succeed Aidan Murphy, EVP Technical Operations and Member of the ELT, who after 30 years of excellent servic...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
VTGN
LISTED
NASDAQ
Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTGN Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit
News Preview
Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of...
Themefolio
Profiler
Peergroup
© Newsfile
27.01.2026
CHS
LISTED
TSX
Comprehensive Healthcare Systems Upsizes Non-Brokered Private Placement
News Preview
Calgary, Alberta--(Newsfile Corp. - January 26, 2026) - Comprehensive Healthcare Systems Inc. (TSXV: CHS) (the "Company" or "CHS"), an industry leader in healthcare benefits administration software and services, announces that due to strong interest from investors, it will increase the size of its previously announced non-brokered private placement...
Themefolio
Profiler
Peergroup
© PR Newswire
26.01.2026
4DX
LISTED
ASX
4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
News Preview
Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and moreLOS ANGELES and MELBOURNE, Australia, Jan. 26, 2026 /PRNewswire/ -- 4DMedical, the leader in software-based respiratory imaging technolo...
Themefolio
Profiler
Peergroup
© BusinessWire
26.01.2026
RCUS
LISTED
NYSE
Arcus Biosciences Announces New Employment Inducement Grants
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to...
Themefolio
Profiler
Peergroup
© PR Newswire
26.01.2026
BIOA B
LISTED
STO
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
News Preview
STOCKHOLM, Sweden, Jan. 26, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to the European Medicines Agency (EMA) for a once every four weeks intravenous (IV) infusion maintenance dosing for lecanemab.
In the EU, lecanemab is...
Themefolio
Profiler
Peergroup
© BusinessWire
26.01.2026
RVTY
LISTED
NYSE
Revvity Board Declares Quarterly Dividend
News Preview
The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Rev...
Themefolio
Profiler
Peergroup
© BusinessWire
26.01.2026
QGEN
LISTED
NYSE
QIAGEN Appoints Mark Stevenson to Supervisory Board
News Preview
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026.
In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on Jan...
Themefolio
Profiler
Peergroup
© BusinessWire
26.01.2026
DFTX
LISTED
NASDAQ
Definium Therapeutics Announces New Employee Inducement Grants
News Preview
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-ex...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.01.2026
CRNX
LISTED
NASDAQ
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
News Preview
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a busine...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.01.2026
STEX
LISTED
NASDAQ
Streamex Corp. (NASDAQ: STEX) Announces Closing of $35 Million Public Offering
News Preview
WINTER PARK, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization of real-world assets and commodity-backed stablecoins, including GLDY, today announced the closing of its previously announced underwritten public offering, including a group of technology...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.01.2026
PRCT
LISTED
NASDAQ
PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City
News Preview
SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.01.2026
CCCC
LISTED
NASDAQ
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Director...
Themefolio
Profiler
Peergroup
© ActuNews
26.01.2026
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 26 januari 2026 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparantiekennisgeving...
Themefolio
Profiler
Peergroup
© ActuNews
26.01.2026
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – January 26, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on January 23, 2026, from Atlas Special Oppo...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.01.2026
SKAN
LISTED
SIX
Dr. Christian Schlögel wird als neues Mitglied des Verwaltungsrats nominiert
News Preview
SKAN AG
/ Schlagwort(e): Personalie
Dr. Christian Schlögel wird als neues Mitglied des Verwaltungsrats nominiert
26.01.2026 / 17:45 CET/CEST
Medienmitteilung
Dr. Christian Schlögel wird als neues Mitglied des Verwaltungsrats nominiert
Allschwil, 26. Januar 2026 – Der Verwaltungsrat der SKAN Group AG schlägt der Genera......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.01.2026
SKAN
LISTED
SIX
Dr. Christian Schlögel nominated as new member of the Board of Directors
News Preview
SKAN AG
/ Key word(s): Personnel
Dr. Christian Schlögel nominated as new member of the Board of Directors
26.01.2026 / 17:45 CET/CEST
Media Information
Dr. Christian Schlögel nominated as new member of the Board of Directors
Allschwil, January 26, 2026 – The Board of Directors of SKAN Group AG proposes Dr. Christian S......
Themefolio
Profiler
Peergroup
© PR Newswire
26.01.2026
ARDX
LISTED
NASDAQ
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
News Preview
Issued on behalf of Avant Technologies Inc.Equity Insider News CommentaryVANCOUVER, BC, Jan. 26, 2026 /PRNewswire/ -- The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for high-tech cures for long-term illness. A major FDA move at the beginning of the yea...
Themefolio
Profiler
Peergroup
© PR Newswire
26.01.2026
ARDX
LISTED
NASDAQ
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
News Preview
Issued on behalf of Avant Technologies Inc.Equity Insider News CommentaryVANCOUVER, BC, Jan. 26, 2026 /CNW/ -- The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for high-tech cures for long-term illness. A major FDA move at the beginning of the year[2] is...
Themefolio
Profiler
Peergroup
© PR Newswire
26.01.2026
LNAI
LISTED
NASDAQ
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
News Preview
AI Platform Achieves Key Milestones, Triggering Launch of Alcohol Use Disorder ProgramSACRAMENTO, Calif. , Jan. 26, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution,...
Themefolio
Profiler
Peergroup
© BusinessWire
26.01.2026
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF T...
Themefolio
Profiler
Peergroup
© BusinessWire
26.01.2026
ERF
LISTED
EURONEXT
Eurofins CDMO Alphora Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening Software
News Preview
Eurofins CDMO Alphora is excited to announce the development and launch of a new AI-powered software for high throughput salt and co-crystal screening – now a core component of all solid-state screening programs. Developed by Eurofins CDMO Alphora, in collaboration with a local university, this cutting-edge machine learning platform provides highl...
Themefolio
Profiler
Peergroup
© BusinessWire
26.01.2026
HUM
LISTED
NYSE
Humana Launches $3 Million Scholarship Fund for Xavier Ochsner College of Medicine to Expand Physician Workforce in Louisiana
News Preview
Humana Inc. (NYSE: HUM) has established a $3 million scholarship fund for incoming medical students at Xavier Ochsner College of Medicine (XOCOM) to help address physician workforce shortages and improve access to healthcare for communities across Louisiana.
This press release features multimedia. View the full release here: https://www.businessw...
Themefolio
Profiler
Peergroup
© PR Newswire
26.01.2026
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
News Preview
SAN DIEGO, Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation, selective inhibitor of the vesicular monoamine transporter 2 (VMAT2). Building on nearly...
Themefolio
Profiler
Peergroup
© PR Newswire
26.01.2026
THAR
LISTED
NASDAQ
Tharimmune Announces Expanded Role as Super Validator on Canton Network
News Preview
Advances Digital Asset Treasury Strategy Through Contributions to Canton Network NEW YORK, Jan. 26, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced...
Themefolio
Profiler
Peergroup
© PR Newswire
26.01.2026
XRAY
LISTED
NASDAQ
Wellspect HealthCare Launches Surity™ Female External Catheter Improving Care for Women Living with Severe Urinary Incontinence
News Preview
MÖLNDAL, Sweden, Jan. 26, 2026 /PRNewswire/ -- Wellspect HealthCare, a global provider of continence care solutions, today announced the U.S. launch of the innovative Surity™ Female External Catheter, a new non-invasive solution designed to support women living with severe urinary incontinence. Wellspect HealthCare has been a trusted healthcare le...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.01.2026
ISRG
LISTED
NASDAQ
Da Vinci 5 Cleared for Cardiac Procedures
News Preview
FDA 510(k) clearance expands da Vinci 5 indications to include certain cardiac procedures FDA 510(k) clearance expands da Vinci 5 indications to include certain cardiac procedures...
Themefolio
Profiler
Peergroup
© Newsfile
26.01.2026
PHIO
LISTED
NASDAQ
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
News Preview
Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio a...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
